Khartis Therapeutics Secures $50M Series B for Thyroid Eye Disease Treatment
Khartis Therapeutics, a San Diego biotech, raised $50 million in a Series B round led by Forge Life Science Partners, Longwood Fund, and Lilly Asia Ventures. The funding brings the company's total capital since inception to an undisclosed amount, supporting development of a drug for thyroid eye disease (TED). The round also included other investors, though details on Zealand's royalty deal were not provided in the announcement.
Related stories
Biotech firms AbCellera, Silence Therapeutics, and InduPro secure substantial capital raises · Drug development
Abcuro secures $66 million to advance Phase 3 trial in milder form of muscle disease · Drug development
PTC Therapeutics and Eli Lilly acquire Sangamo assets in bankruptcy auction · Drug development
ARCH and Population Health partner with Haisco in China push · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Zealand's royalty deal; Khartis raises money for TED drug.” Browse more stories.